Human myeloid dendritic cells for cancer therapy: does maturation matter?
|Year of publication||2010|
|Type||Article in Periodical|
|Magazine / Source||Vaccine|
|MU Faculty or unit|
|Field||Oncology and hematology|
|Keywords||Dendritic cells; Cancer vaccine; Maturation cocktails|
|Description||Dendritic cells form the connection between innate and adoptive mechanisms of the immune system. As antigen-presenting cells, dendritic cells are capable of presenting tumour antigen and effectively stimulating immune response targeted against a tumour. A number of preclinical and clinical studies document dendritic cells' potential in anti-cancer treatment. Increasing knowledge of dendritic cell biology is leading to improved methods for their preparation for clinical application. Unfortunately, there is to date no consensus specifying optimal conditions for dendritic cell preparation in vitro. This review summarizes the methods used for preparing myeloid dendritic cells derived from monocytic precursors while focusing on cytokine cocktails used for their growth, maturation, and functional adjustment.|